What are your top takeaways in Head & Neck Cancers from ASCO 2026?

• I think Abstract 103, the impact of reduced-dose RT for hPV+ oropharyngeal, is by far the most impactful.
• The post op phase III randomized oral cavity cancer trial that showed post-op RT improves locoregional control is important.

Here are a couple of studies that I thought deserve comment:

The group from Tata Memorial Hospital presented a prospective randomized study of post-op RT or observation in patients with pT1-2N0 with one or more intermediate risk factors (Nair et al., ASCO 2026). The patients underwent surgery with ad...